Hence, CD19 targeting reagents might be not only suitable for treating B cell malignancies, but also exhibit great potential for therapeutic use in autoimmune diseases, particularly for those diseases with a strong involvement of pathogenic antibodies, e.g., SLE, pemphigus, and neuromyelitis optica. Here, CD19 is linked to autoimmune disease.